Key Details
Annual ROE
-518.56%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 08, 2023Recent annual earnings:
Feb 28, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with RETA included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Similar stocks
CPMG Inc (Trades, Portfolio), a prominent investment firm, recently expanded its portfolio with the acquisition of a substantial number of shares in Reata Pharmaceuticals Inc. This article provides an in-depth analysis of the transaction, the profiles of both CPMG Inc (Trades, Portfolio) and Reata Pharmaceuticals Inc, and the potential implications of this significant investment.
Reata Pharmaceuticals (NASDAQ: RETA ) stock is soaring higher on Friday as investors react to an acquisition deal with Biogen (NASDAQ: BIIB ). That deal has Biogen offering to buy shares of RETA stock for $172.50 per share in cash.
Shares of Reata Pharmaceuticals Inc (NASDAQ: RETA) opened more than 50% up this morning after Biogen Inc (NASDAQ: BIIB) said it will buy the pharma company for $7.3 billion. Why is Biogen making this acquisition?
Reata's (RETA) prior approval supplement application to update the drug substance specification for Skyclarys gets FDA's nod. Shares of the company gain 7% on Wednesday in response.
Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12 – 15, 2023, in Dana Point, California. Manmeet Soni, Reata's President, Chief Operating Officer, and Chief Financial Officer will be.
Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Warren Huff - Chairman and Chief Executive Officer Dawn Bir - Executive Vice President and Chief Commercial Officer Andrea Loewen - Senior Vice President of Global Regulatory Affairs Seemi Khan - Senior Vice President and Chief Medical Officer Colin Meyer - Executive Vice President and Chief Innovation Officer Manmeet Soni - President, Chief Operating Officer and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Kumar - Goldman Sachs Yatin Suneja - Guggenheim Securities Charles Duncan - Cantor Fitzgerald Carter Gould - Barclays Annabel Samimy - Stifel Maury Raycroft - Jefferies Matthew Kaplan - Ladenburg Thalmann Operator Thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results Update on Operational Progress and Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investor section of Reata's website at reatapharma.com.
FAQ
- What is the primary business of Reata Pharmaceuticals?
- What is the ticker symbol for Reata Pharmaceuticals?
- Does Reata Pharmaceuticals pay dividends?
- What sector is Reata Pharmaceuticals in?
- What industry is Reata Pharmaceuticals in?
- What country is Reata Pharmaceuticals based in?
- When did Reata Pharmaceuticals go public?
- Is Reata Pharmaceuticals in the S&P 500?
- Is Reata Pharmaceuticals in the NASDAQ 100?
- Is Reata Pharmaceuticals in the Dow Jones?
- When was Reata Pharmaceuticals's last earnings report?
- When does Reata Pharmaceuticals report earnings?
- Should I buy Reata Pharmaceuticals stock now?